Redeye comments on the SEK29.4m rights issue of units and the restructuring initiatives by reducing ...
Redeye comments on Truecaller ahead of its Q2 results, which are due on 18 July.
Rec. PTP -7% vs ABGSCe Vacancies up slightly, property value down -0.
Redeye judges that FluoGuide’s recently released progress update mostly confirms our expectations.
Duell’s Q3 figures were anticipated to be weak following the profit warning.
Redeye initiates coverage of q.beyond, a German IT service provider.
Prolight announced that its rights issue was fully subscribed, eliminating near-term financing risk ...
Market remains muted, but new contracts are positive Targets challenging (earnings likely to land be...
Redeye comments on Genovis’ decision to acquire the remaining 75% of SEQURNA, viewing it as a logica...
Redeye comments on the outcome of Jumpgate’s rights issue.
Redeye comments on Eniro's acquisition of Qwamplify Nordics, a company within digital campaign produ...
Redeye gives a preview ahead of Sdiptech's Q2 2025 report, due on July 18.
Q2'25 numbers due on 24 July at 07:45 CET Adj. EBITDA flat, EBIT up 2% for '25e-'27e Unchanged story...
Redeye provides a short comment on Scandinavian ChemoTech announcing sales of USD390k in the second ...
Q2 report Friday, 18 July at 12:00 CET '25e-'27e adj.
Redeye comments on the outcome of Initiator Pharma’s recent rights issue.
Redeye comments on W5 Solutions announcement of a directed share issue totalling cSEK104m which stre...
Duell lowered its guidance for FY 2025 as weakened market conditions resulted in weaker-than-expecte...
Organic growth could remain close to zero for H1 2025E y/y, but acquisitions should at least offer 6...
Today, Suominen announced imminent change of the CEO.
